학술논문
The survival impact of preoperative FOLFOX for resectable locally advanced rectal cancer: the R-NAC-01 study.
Document Type
Article
Author
Ichikawa, Nobuki; Homma, Shigenori; Funakoshi, Tohru; Hattori, Masahiro; Sato, Masanori; Kamiizumi, You; Omori, Kazuyoshi; Nomura, Masaru; Yokota, Ryoichi; Koike, Masahiko; Kon, Hirofumi; Takeda, Keisa; Ishizu, Hiroyuki; Matsuoka, Shinichi; Hirose, Kunihiro; Ishikawa, Takahisa; Murata, Ryohei; Iijima, Hiroaki; Yoshida, Tadashi; Minagawa, Nozomi
Source
Subject
*RECTAL cancer
*ANTINEOPLASTIC combined chemotherapy protocols
*RECTAL surgery
*ADJUVANT chemotherapy
*PELVIC exenteration
*NEOADJUVANT chemotherapy
*
*
*
*
*
Language
ISSN
0941-1291
Abstract
Purpose: In this follow-up of the R-NAC-01 study, we assessed the long-term oncological benefit of four courses of modified leucovorin, 5-fluorouracil (FU), and oxaliplatin (mFOLFOX6) chemotherapy before rectal surgery. Methods: In this prospective, multicenter study (UMIN 000012559) involving 11 hospitals in Japan, patients with lower rectal cancer underwent four cycles of mFOLFOX6 chemotherapy and subsequent surgery within four to six weeks. The 3-year recurrence-free survival and local recurrence rates were then reported. Results: Of 41 patients (36 males, 5 females; mean age: 60.8 years old) who received 4 courses of chemotherapy, 40 underwent total mesorectal excision, and 1 underwent total pelvic exenteration. R0 resection was achieved in 40 patients, but none showed a pathological complete response. Twenty-nine patients received adjuvant chemotherapy for an average of 4 months. The 3 year recurrence-free survival and local recurrence rates in patients undergoing curable resection were 72.8% and 8.5%, respectively. cStage III patients with adjuvant chemotherapy had a significantly higher 3 year recurrence-free survival than those without adjuvant chemotherapy (76.6 vs. 40.0%, log-rank p = 0.03). Conclusion: Four courses of mFOLFOX6 chemotherapy before surgery may be a promising treatment strategy for locally advanced rectal cancer. Adjuvant chemotherapy might be needed for cStage III patients, even after four courses of neoadjuvant mFOLFOX6. [ABSTRACT FROM AUTHOR]